Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Advances in CD22/CD19 CAR-T sequential therapy

Jianxiang Wang • 6 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia CAR-T

In this video, Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, talks on CAR-T therapy for the treatment of acute lymphoblastic leukemia (ALL). Dr Wang discusses the need to reduce the risk of relapse following CD19 CAR-T therapy and describes ongoing trials investigating CD22/CD19 CAR-T sequential therapy, which demonstrate high efficacy and a prolonged duration of remission. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Advisor of AbbVie

More from Jianxiang Wang

4:47
COMMODORE: gilteritinib for the treatment of R/R FLT3-mutated AML
Jianxiang Wang • 6 Jun 2022
3:13
The clinical characteristics and prognosis of adults with Ph-ALL with TP53 aberrations
Jianxiang Wang • 6 Jun 2022
2:12
Progression of CAR-T trials in China
Jianxiang Wang • 2 Feb 2021
3:14
CAR-T trials to watch in China
Jianxiang Wang • 2 Feb 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals